SLDB (Solid Biosciences) Research & Development: $155.55 Mil (TTM As of Mar. 2026)


SLDB Solid Biosciences Inc SLDB
34 GF Score
Price $9.27
! 2 Warning Signs
View Full Analysis

What is Solid Biosciences Research & Development?

Solid Biosciences SLDB +4.85% 34 Research & Development is $155.55 Mil as of Mar. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Solid Biosciences's Research & Development for the three months ended in Mar. 2026 was $46.14 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $155.55 Mil.

Solid Biosciences  (NAS:SLDB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Solid Biosciences Research & Development Related Terms

Solid Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Solid Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solid Biosciences Research & Development Chart

Solid Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.74 78.42 76.56 96.43 140.33

Solid Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.91 32.42 38.86 38.14 46.14
SLDB
34GF Score
Solid Biosciences Inc SLDB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solid Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $155.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $155.55 Mil mean?
Solid Biosciences (SLDB) has a Research & Development of $155.55 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Solid Biosciences and its competitors.
Is Solid Biosciences' Research & Development too high?
Solid Biosciences' current Research & Development is $155.55 Mil. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Research & Development compare to REPL and BBOT?
Solid Biosciences' Research & Development of $155.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Solid Biosciences and its competitors. Solid Biosciences's current Research & Development is $155.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Research & Development of $155.55 Mil. The current Research & Development is $155.55 Mil. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Research & Development is $155.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solid Biosciences Business Description

Address 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score

Get the complete analysis for SLDB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.27
Price